Abstract
The intrepid young oncologist's criticism of cancer screening and surrogate endpoints has stirred up controversy. He says he just wants drugmakers, others to meet high standards of evidence.
Original language | English (US) |
---|---|
Volume | 2016 |
No | OCT |
Specialist publication | Managed Care |
State | Published - 2016 |
ASJC Scopus subject areas
- Medicine(all)
- Health Policy
- Public Health, Environmental and Occupational Health